Dexrazoxane ameliorates radiation-induced heart disease in a rat model

Long Li¹, Xiaoqi Nie¹, Peng Zhang¹, Yongbiao Huang¹, Li Ma¹, Fang Li¹, Minxiao Yi¹, Wan Qin¹, Xianglin Yuan¹

¹Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei Province, China

Correspondence to: Xianglin Yuan; email: yuanxianglin@hust.edu.cn

Keywords: radiation-induced heart disease, dexrazoxane, apoptosis, reactive oxygen species, rat model

Received: July 8, 2020  Accepted: November 3, 2020  Published: January 2, 2021

ABSTRACT

Treatment of thoracic tumors with radiotherapy can lead to severe cardiac injury. We investigated the effects of dexrazoxane, a USFDA-approved cardioprotective drug administered with chemotherapy, on radiation-induced heart disease (RIHD) in a rat model. Male Sprague-Dawley rats were irradiated with a single dose of 20 Gy to the heart and treated with dexrazoxane at the time of irradiation and for 12 subsequent weeks. Dexrazoxane suppressed radiation-induced myocardial apoptosis and significantly reversed changes in serum cardiac troponin I levels and histopathological characteristics six months post-radiation. Treatment with dexrazoxane did not alter the radiosensitivity of thoracic tumors in a tumor formation experiment using male nude Balb/C mice with tumors generated by H292 cells. Dexrazoxane reduced the accumulation of reactive oxygen species in rat cardiac tissues, but not in tumors in nude mice. Transcriptome sequencing showed that IKBKE, MAP3K8, NFKBIA, and TLR5, which are involved in Toll-like receptor signaling, may be associated with the anti-RIHD effects of dexrazoxane. Immunohistochemistry revealed that dexrazoxane significantly decreased NF-κB p65 expression in cardiomyocytes. These findings suggest dexrazoxane may protect against RIHD by suppressing apoptosis and oxidative stress in cardiomyocytes.

INTRODUCTION

Approximately 70% of all cancer patients receive radiotherapy at some point during their treatment [1]. Oncologists are actively examining the adverse effects of radiotherapy on the heart. The first case of radiotherapy-induced cardiac death was reported in 1963 [2]. In addition, increased rates of RIHD have been observed in long-term survivors of breast cancer [3] and lymphoma [4] over decades of follow-up. Moreover, RIHD is detected shortly after the completion of radiotherapy in patients with some types of tumors. Approximately 10.3% of patients with locally advanced lung cancer experience major adverse cardiac events (MACE) within 20 months after radiotherapy. The risk of MACE was significantly higher in patients who received a mean heart dose (MHD) of more than 10 Gy [5]. Furthermore, the risk of major coronary events increased linearly with MHD by 7.4% per Gy and persisted up to 30 years after radiotherapy in breast cancer patients [3]. Although cardiac damage caused by irradiation persists for long periods, relatively little is known about this condition. A Norwegian study on long-term survivors of childhood malignant lymphomas reports that, although 34% of patients were aware of the risk of long-term side-effects of radiotherapy, only 13% routinely attended follow-ups [6].

Cardiovascular toxicity is the leading cause of death in long-term survivors of breast cancer, especially in patients with early stages [7], and the second leading cause of mortality in cancer survivors [8]. The number of cancer survivors globally is expected to pass 22
million by 2030 due to advances in medical treatment and increases in lifespan in general [9]. As the number of cancer survivors increases, the number experiencing RIHD would also likely increase, possibly offsetting some benefits of thoracic radiation. Epidemiological studies have improved our understanding of RIHD, and increased precision in radiation dosing techniques results in smaller doses being absorbed by the cardiovascular system. However, there are no clinically effective drugs that can be used to prevent or reverse the onset and progression of RIHD [10].

The growing field of “cardio-oncology” is examining the cardiotoxic effects of some anti-tumor drugs, including anthracyclines, antimetabolites, and targeted drugs [11–13]. Cardiotoxicity induced by antineoplastic drugs is partly associated with oxidative stress (OS) [14]. Excessive accumulation of free radicals and reactive oxygen species (ROS) can damage mitochondrial function, cause cell damage, trigger cell apoptosis, and consequently lead to cardiac dysfunction [15]. Although the exact molecular mechanisms of RIHD are not completely understood, endothelial and mitochondrial injuries, the endoplasmic reticulum, and OS play significant roles in its etiology. Radiation damage to normal tissues is due to direct exposure to high intensity radiation energy and indirect oxidative stress caused by ROS. Because of its weak antioxidant defense, the myocardium is susceptible to oxidative damage caused by free radicals generated during irradiation [16].

Pharmacological agents including beta blockers, statins, and dexrazoxane (DZR) demonstrate potential cardioprotective effects in patients receiving anthracycline or trastuzumab, although more extensive clinical trials are needed to evaluate these effects [13]. DZR is recommended by the USFDA to prevent anthracycline cardiotoxicity. DZR significantly reduces anthracycline-induced cardiotoxicity without altering its antitumor efficacy, dosing frequency, toxicity, or secondary malignancy rates compared to control groups [17–20]. However, the role of DZR in RIHD has not yet been studied to our knowledge.

In this study, we examined whether DZR played a cardioprotective role and prevented radiation-induced damage in a rat model of RIHD.

**RESULTS**

**DZR ameliorates myocardial injury induced by irradiation in rats**

To investigate the radioprotective effect of DZR in cardiomyocytes, we examined changes in the levels of proteins related to the apoptotic pathway in H9C2 cells after radiotherapy. Different concentrations of DZR (100 μM, 200 μM, and 400 μM) were added to H9C2 cells an hour before they received 10 Gy irradiation. The effects of DZR on radiation-induced myocardial cell injury were assessed 24 hours later by a Western blot apoptosis assay. As shown in Figure 1G, expression of the proapoptotic proteins Bax, Caspase-3, and cleaved caspase-3 (C-caspase-3) increased, while expression of the antiapoptotic protein Bcl-2 declined markedly, in irradiated H9C2 cells. Furthermore, DZR pretreatment (200 or 400 μM) inhibited the radiation-induced increase in pro-apoptotic protein expression and decrease in Bcl-2 expression. These results indicate that the radioprotective effects of DZR in *vitro* were partially due to an inhibition of pro-apoptosis signaling.

Next, we used a rat model to evaluate the cardioprotective role of DZR in radiation-induced heart injury *in vivo*. Echocardiography was performed every 4 weeks to assess changes in cardiac function associated with RIHD. Type M-mode sonograms used to measure left ventricular ejection fraction (EF) are shown for each group in Figure 1A. EF decreased significantly in RT rats compared to CON rats at 4 (p=0.012) and 8 weeks (p=0.034). This reduction was significantly reversed in the RT+ H-DZR treatment group at 8 weeks (p=0.007), but no significant differences were observed between the groups during the subsequent observation period, suggesting the presence of an acute injury with a later recovery (Figure 1F). Histological evaluation also showed that DZR protected against RIHD as indicated by decreases in chronic fibrosis. HE staining (Figure 1B) and Masson’s trichrome staining (Figure 1C) revealed that cardiomyocytes in RT rats exhibited breakdown, edema, disordered arrangement, twisted myocardial fibers, nuclear condensation, interstitial fiber deposits, and increased numbers of inflammatory cells. Furthermore, transmission electron microscopy (TEM) showed evidence of profound cardiomyopathy-associated subcellular changes. Mitochondria of RT rats exhibited hyperplasia and hypertrophy, appearing swollen with widened or broken cristae. In addition, abnormal sarcomeres, expanded sarcoplasmic reticulum, myofibrilament fractures, partial focal dissolution, widening of the myo-interstitial space, and deposition of collagen fibers were observed in RT rats. These abnormalities were partially alleviated by DZR treatment, especially in the high dose group (Figure 1D). At week 24, 7 rats in the RT group had died (most within 8 weeks after irradiation), while 4 and 6 rats had died in the RT+ H-DZR and RT+ L-DZR groups, respectively. Although DZR treatment appeared to prolong survival in rats, this effect did not reach statistical significance (Figure 1E). Serum cardiac
troponin I (cTnI) levels were significantly increased in the RT group compared to the other groups, suggesting that myocardial injury occurred in rats exposed to radiation. However, this increase was reduced in the RT+L-DZR (p=0.02) and RT+H-DZR (p<0.01) groups (Figure 1H). These results indicate that the rat model of RIHD was successfully established and that DZR may protect against the development of RIHD.

**Treatment with DZR does not alter radiosensitivity of thoracic cancer in vivo**

After establishing the radioprotective effects of DZR on RIHD, we used a xenograft model to investigate whether DZR reduced radiosensitivity in thoracic tumors in vivo. In a subcutaneous tumor model generated by transplanting H292 cells, tumor volumes met the criteria for establishing experimental groups at 10 days after injection. There were no significant differences in tumor volume among the four groups during the initial observation period. Irradiation significantly decreased tumor volume and weight compared to the control groups beginning at 12 days after treatment (p<0.01), but no obvious differences were observed between the RT group and the RT+DZR group. (Figure 2A–2C). These results indicated that DZR did not reduce the sensitivity of thoracic tumors to radiotherapy in nude mice.

**DZR inhibits RIHD-associated apoptosis by decreasing ROS generation in heart tissue, but not in tumor tissue, after irradiation**

Numbers of apoptotic cardiomyocytes were significantly higher in RT group rats than in CON and RT+H-DZR group rats (referred to as RT+ DZR) for 6 months after irradiation (Figure 3A). The apoptosis rate was 14.37 ± 1.92% in the RT group and 2.04 ± 0.54% in the DZR group. These results indicated that DZR may protect against the development of RIHD.

---

**Figure 1. Dexrazoxane decreases functional damage and structural injury in the rat heart after irradiation.** (A) Representative M-mode echocardiograms for each group. (B, C) Representative HE and Masson staining (×200, scale bar =100 μm) of hearts from each group (n=7-11, respectively). (D) Subcellular abnormalities in mitochondria, sarcomeres, and myofilaments identified by TEM (×10K). (E) Kaplan-Meier analysis of rat survival in each group. Exposure to whole heart irradiation significantly reduced overall survival time (CON vs RT, p =0.029). A non-significant trend for a long-term survival benefit of DZR was observed. (F) Irradiation significantly decreased EF in rats within 8 weeks. No significant differences were observed among the groups (n=3 at every time point for each group) after 8 weeks. (G) H9C2 cells were pre-treated with or without DZR (100, 200, and 400 μM) before a single 10 Gy X-ray irradiation. 24 h after irradiation, radiation-induced apoptosis-related injuries were reduced in cardiomyocytes pre-treated with 200 and 400 μM DZR. (H) Serum levels of cardiac troponin I (cTnI) were assessed at week 24 after irradiation. cTnI levels in CON and DZR groups were 30.13 ± 7.94 and 36.58 ± 8.97 pg/mL (n=5), respectively. Irradiation significantly increased cTnI levels in irradiated rats. cTnI levels were as follows: 147.00 ± 2.46 pg/mL in RT group (vs CON, p<0.01, n=8), 78.95 ± 12.81 pg/mL in RT+H-DZR group (vs RT, p<0.01, n=11), 110.80 ± 11.36 pg/mL in RT+L-DZR group (vs RT, p<0.05, n=9). Data are expressed as mean ± SEM, *: p<0.05, **: p<0.01.

---

**www.aging-us.com** 3701 **AGING**
in RT+ DZR group (p<0.01) (Figure 3D). This suggests that DZR reduced radiation-induced apoptosis in cardiomyocytes in vivo. In order to investigate the antioxidant activities of DZR, we used a DCFH-DA fluorescence assay to measure ROS in frozen cardiomyocytes from rats and in tumors from nude mice. We found that irradiation increased ROS generation in the rat heart compared to the CON group (p<0.01) (Figure 3B, 3E). Furthermore, combined treatment with DZR significantly reversed radiation-induced ROS generation (p<0.01). However, no obvious fluorescence intensity differences indicative of ROS production were observed in tumors from nude mice among the experimental groups (Figure 3C, 3F). This suggests that DZR reduced apoptosis in normal heart tissues without altering the therapeutic effects of radiotherapy. This might be a result of selective suppression of radiation-induced ROS generation in rat cardiomyocytes and not in tumor tissue from nude mice.

**Reduction of Toll-like receptor/NF-κB signaling pathway mRNA expression is involved in the anti-RIHD effects of DZR in the rat model**

In order to elucidate the mechanisms underlying the protective effects of DZR against RIHD, gene expression in cardiac tissue from RT+ DZR and RT group rats was analyzed using transcriptome sequencing (Figure 4A). The heat map revealed that transcription of four genes involved in the Toll-like receptor signaling pathway, *IKBKE, MAP3K8, NFKBIA*, and *TLR5*, was significantly inhibited in the RT+ DZR group compared to the

---

**Figure 2. Radiotherapy combined with DZR treatment does not inhibit tumor growth in vivo.** (A) Tumor images for each group. (B) Tumor volume changes in nude mice over time. (C) Final tumor weight in nude mice; data are expressed as mean ± SEM, *: p <0.05, **: p <0.01.
RIHD group (Figure 4B). KEGG pathway analysis of gene set enrichment indicated that gene clusters associated with the Toll-like signaling pathway were downregulated after DZR treatment (Figure 4C). Immunohistochemical analysis revealed that NF-κB subunit p65 protein expression was significantly higher in cardiomyocytes from the RT group (24.42%) compared to the control group (7.61%) (p<0.01). Furthermore, p65 expression was significantly decreased in RT+ DZR rats (p<0.01, Figure 4D, 4E). These findings suggest that the Toll-like/NF-κB pathway was important for the anti-RIHD effects of DZR; this pathway might therefore also play an important role as a downstream effector after activation by ROS.

**DISCUSSION**

Advances in precision radiotherapy techniques can be accompanied by adverse effects which extend to several organs. Thoracic radiation therapy can potentially affect all cardiac structures. Patients may develop RIHD, which decreases the survival benefits of anti-cancer treatment, several years after treatment has ended [21]. Strategies to protect against RIHD are therefore needed. A multicenter phase III clinical trial showed that DZR significantly alleviates anthracycline-induced cardiac events (13% vs 39%, p<0.001) [22]. The European Society of Cardiology states that DZR significantly reduces the risk of heart failure in adult cancer patients treated with anthracycline without affecting the tumor-response rate [23]. In this study, we demonstrated the cardioprotective effects of DZR both in vitro and in vivo.

Among stage III NSCLC patients treated with chemoradiotherapy, overall survival was higher among those treated with 60 Gy radiation than those treated with 74 Gy, and excessive cardiac irradiation doses were a predictor of poor survival. Incidence of RIHD significantly increased when the mean dose to the heart was more than 20 Gy [24–26]. Relatively few animal studies examining RIHD have been conducted, and most are based on rat models. One study found that when the dose of a single radiation administered to the rat heart increased from 18 Gy to 24 Gy, cardiomyocytes were more severely damaged or were even replaced by interstitial fibrosis within six months after irradiation [27]. In the present study, partial...
myocardial fracture and interstitial fibrosis were observed in histological assessments of the rat heart after a single irradiation of 20 Gy, which was consistent with previous studies [28]. In addition, most of the rats that died after radiotherapy did so within eight weeks, which is consistent with echocardiography results showing significant EF reduction within eight weeks after radiotherapy. This suggests that acute cardiac injury after radiotherapy might have been the main cause of death in the animals in this study. Although we did not observe a significant DZR-associated improvement in rat survival times after irradiation, acute radiation damage to numerous other vital organs around the heart, such as the lungs, thymus, and esophagus, might also have caused the deaths of experimental animals in this study after high doses of radiation. We therefore evaluated the radio-protective effects of DZR on the heart in histopathological examinations.

Figure 4. Gene expression profile in heart tissue from the RIHD rat model. (A) Results of transcriptome sequencing of tissue samples from RT and RT+H-DZR rats. (B) Gene expression profiles of Toll-like signaling pathway members were examined using a heat map. Red, high expression; white, intermediate expression; blue, low expression. (C) Top 30 enriched pathways identified using distribution points of differential genes in KEGG pathway analysis. The horizontal axis represents the enrichment factor, point size indicates the number of differential genes in the pathway, and the color of the points corresponds to different Q-value ranges. T indicates RT+H-DZR, R indicates RT. (D, E) show NF-κB-p65 protein levels (×100, scale bar =250 μm; ×400, scale bar =50 μm) in myocardial tissue determined by immunohistochemistry (n=5 per group). mean ± SEM, *: p <0.05, **: p <0.01.
DZR markedly inhibited the expression of pro-apoptotic proteins in H9C2 cells and reduced the number of apoptotic cardiomyocytes in rats after exposure to radiation. Apoptosis is an important pathological mechanism in radiation-induced tissue damage and is also observed in radiation-induced pulmonary fibrosis [29]. RIHD develops many years after irradiation in a dose-dependent manner, and the damage worsens over time, leading to fibrosis in heart tissue [30]. Apoptosis rate is closely associated with the severity of radiation-induced myocardial injury [31]. In the present study, histological evaluation showed myocardial interstitial fibrosis and abnormalities in cardiac mitochondria six months after radiation. The pathological developments in our rat model were therefore consistent with those observed in RIHD. In addition, mitochondrial damage was observed when myocardial tissues from irradiated rats were examined using TEM. Mitochondria are particularly susceptible to radiation-induced damage, and mitochondrial damage is related to changes in levels of apoptosis proteins including Bax, which are associated with the severity of radiation-induced cardiac injury [16]. Cardiac troponins are also markers of myocardial injury. In a prospective clinical study, serum troponin was an effective predictor of chemotherapy-related cardiac injury, suggesting that troponin-targeting treatment strategies may be effective [32]. Serum cTnI levels increased significantly after radiation and improved after DZR treatment in our study. However, echocardiography did not show similar results. We observed a decrease in EF soon after radiation, but this decrease disappeared over time. In contrast, a significant radiation-induced increase in EF was observed in another rat RIHD model after fractionated doses of 9 Gy for 5 fractions [33]. Our results are consistent with those of another previous study which found no differences in EF between the radiated and control groups in a rat RIHD model 5 months post-radiation when a single high dose of 20 Gy was used [34]. It is possible that a decrease in EF after radiation might be observed only after higher radiation doses and prolonged follow-up. Additionally, changes in EF might not always accompany myocardial injury, apoptosis, and interstitial fiber deposits, perhaps due to compensatory mechanisms in the heart. In summary, our results suggest that DZR may protect against RIHD.

Although RIHD is not well-understood, it is associated with an imbalance between the production and scavenging of ROS, which results in damage to cellular lipids, proteins, and DNA [35]. The heart is particularly vulnerable to ROS damage because it has lower antioxidant levels than other tissues and because its membrane structures are rich in phospholipids that are particularly sensitive to ROS [36]. Studies demonstrate that both acute and chronic excessive ROS production caused by antineoplastic drugs promote pathogenesis in cardiovascular disease [37]. Here, we found that irradiation caused mitochondrial damage and increased ROS production in the heart. This indicates that the anti-RIHD effects of DZR may be related to reduced ROS levels in the heart. At the same time, irradiation can damage the mitochondria and induce apoptosis of both cardiomyocytes and tumor cells. However, the Warburg effect in tumor cells enables a switch from aerobic oxidation to glycolysis in mitochondria; this metabolic change does not occur in cardiomyocytes [38]. Moreover, abnormally high ROS levels in tumor cells do not cause significant increases in tumor cell death, and malignant tumor development is itself associated with abnormal accumulation of ROS [39]. Given the complexity of oxidative stress regulation in tumor cells, we directly investigated whether DZR affects the efficacy of radiotherapy in vivo. Tumor formation experiments in nude mice indicated that DZR had no significant effect on radiotherapy efficacy in tumor tissues. This might be due to the large amount of ROS continuously produced during tumor-cell proliferation or to differences in ROS regulation mechanisms between cardiomyocytes and tumors. Transcriptome sequencing revealed that genes in the Toll-like signaling pathway were responsible for the therapeutic effect of DZR, and quantification of NF-kB p65 by immunohistochemistry in cardiac tissues confirmed that finding. Upon stimulation by activating inhibitor protein IκB, NF-kB regulates several pathophysiological processes, including inflammation and apoptosis. ROS also impact the NF-kB signaling pathway as a second messenger signal [40], possibly explaining the role of ROS in RIHD.

Some limitations of the present study should be considered when interpreting the results. First, we did not observe a significant improvement in EF or survival after DZR treatment, which may be related to the radiation dose used. A higher radiation dose should therefore be considered in future studies. Second, we did not include other potentially effective drugs as controls when evaluating the cardioprotective effects of DZR on RIHD. Lastly, the relationship between ROS, apoptosis, and NF-kB needs to be studied further to fully elucidate the mechanism underlying DZR’s anti-RIHD effects.

In conclusion, DZR treatment both before and after radiation significantly improved RIHD in a rat model without reducing the therapeutic effect of radiotherapy in a tumor formation experiment. The mechanisms underlying this effect might be related to OS and should be further examined in future studies.
MATERIALS AND METHODS

Cell cultures and irradiation

H292 cells were obtained from Cell Bank, Chinese Academy of Sciences, China and maintained in RPMI/1640 supplemented with 10% fetal bovine serum (Gibco, USA), penicillin (100 U/mL), and streptomycin (100 Ag/mL) with 5% CO₂ at 37° C. Cells were irradiated with a single dose of 8 or 10 Gy using a clinical linear accelerator (6MV X-rays, Elekta Precise, Stockholm, Sweden). In in vitro experiments, DZR was added to the cell culture medium at a concentration of 100, 200, or 400 μM before irradiation per the protocol described in a previous study [41].

Rat heart irradiation and DZR administration

Sixty-five male Sprague-Dawley rats aged 8–10 weeks were obtained from the Experimental Animal Center of Hubei Province and housed in our pathogen-free animal facility with free access to food and water. After one week of acclimatization, they were randomly divided into five groups: control (CON, n=10), dexrazoxane (DZR, n=10), radiation (RT, n=15), radiation with high-dose DZR (a single i.p. dose of 15.6 mg/100 g immediately after irradiation followed by 3.12 mg/100 g i.p. per week until 12 weeks after irradiation, RT+H-DZR, n=15), and radiation with low-dose DZR (a single i.p. dose of 7.8 mg/100 g immediately after irradiation followed by 1.56 mg/100 g per week i.p. until 12 weeks after irradiation, RT+ L-DZR, n=15) (Figure 5).

Rats in the irradiated groups were anesthetized using intraperitoneal chloral hydrate (7%). The whole heart was irradiated with a single dose of 20 Gy using a linear accelerator. Irradiation was performed according to previously published protocols [42, 43] and based on post-anatomical heart size measurements. A medical linear accelerator (Elekta Precise) was used to irradiate one rat at a time. The rat’s limbs were fixed on the plate in the supine position, the center of the irradiation field was aligned with the geometric center of the heart, and a source distance of 100 cm, 180° field, irradiation field size of 2.0 cm×2.0 cm, dose rate of 500 cGy/min, and total dose of 20Gy (6MV X-ray) per administration were used.

All procedures in this study were approved by the Institutional Animal Care and Use Committee of Tongji Hospital affiliated with the Tongji Medical College of Huazhong University of Science and Technology.

![Diagram](image)

**Figure 5.** Dexrazoxane treatment. A single 20 Gy dose was administered to the entire rat heart to simulate RIHD; DZR treatment was administered for 12 weeks post-irradiation. Three randomly selected rats from each group were monitored using high-frequency echocardiography at 4, 8, 12, 16, 20, and 24 weeks post irradiation. All rats were euthanized at 24 weeks; serum and heart tissue samples were collected.
Echocardiography

High frequency (30 MHz) echocardiography (Vevo 2100, VisualSonics Inc, Toronto, Canada) was performed once every month for up to 6 months after irradiation to assess left ventricular function. After shaving their chest hair, rats were initially anesthetized with a 5% isoflurane-O₂ mixture in an induction chamber, and 2% isoflurane-O₂ was then administered during ultrasound procedures while dynamic electrocardiograms were recorded using a gas anesthesia system (isoflurane vaporizer; Ohio Medical Products). M-mode echocardiograms were recorded and analyzed.

Tissue collection and histology

All rats were sacrificed 24 weeks after irradiation. Their hearts were isolated and a tissue sample from each heart was used for TEM. Other tissue samples were partially embedded in paraffin and stained with hematoxylin-eosin and Masson’s trichrome [44]. The remainder of the cardiac tissue was used for transcriptome sequencing, TUNEL staining, and ROS detection.

For TEM, a 1 mm² piece of cardiac tissue was fixed with 2.5% glutaraldehyde and washed with phosphate buffer several times. The tissue was sequentially fixed in 1% osmium acid for one hour and then dehydrated using a series of acetone treatments at room temperature. The sample was then embedded in Epon 618 and cut into ultrathin sections using an ultramicrotome after staining with uranyl acetate and lead citrate. These sections were studied using a transmission electron microscope (HT7700, Hitachi, Tokyo, Japan).

TUNEL assay

To identify myocardial apoptosis, a TUNEL assay was performed on cardiomyocytes using a TUNEL kit (11684817910, Roche, Swiss) and according to the manufacturer’s protocol. TUNEL-positive cardiomyocytes were those that contained both TUNEL staining and DAPI-positive nuclei in heart tissue. In each TUNEL-stained section, five fields were randomly chosen and analyzed using fluorescence microscopy. All slides were individually analyzed by two individual observers in a blinded manner.

Measurement of ROS production

To measure ROS levels in situ using DHE staining, rat heart tissues (n=5 per group) and tumor tissues from nude mice (n=5 per group) were cast into 10 µm frozen sections (LeicaCM1850; Leica Microsystems GmbH). Following the manufacturer’s protocols, these sections were incubated with 5 mM dihydroethidium (KGAF019, Nanjing KeyGen Biotech Co., Ltd., Nanjing, China) for 30 minutes at 37° C. Fluorescence images were obtained using a Carl Zeiss Axioscope A1 microscope. For DHE staining, five fields per sample were randomly chosen and analyzed. DHE fluorescence intensity was quantified using Image Pro Plus (version 1.4.3.67, NIH).

Transcriptome sequencing and data analysis

Total RNA was isolated from cardiac tissues of CON and RT group rats (n=3 per group) to construct cDNA libraries which were then sequenced using the Illumina HiSeq™ 2000 platform (Illumina, San Diego, CA, USA). A p-value<0.05 and |log₂(foldchange)|>1 were used to identify differentially expressed genes (DEGs) between the two groups. Relative abundances were analyzed using a heat map. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis was used to identify biological functions and molecular interaction networks associated with the DEGs.

Tumor formation experiment

Male nude BALB/C mice (4 weeks old, Experimental Animal Center of Hubei Province, Wuhan, China) were housed in the animal facility of our hospital and allowed to adapt to the environment for one week prior to treatment. H292 cells were digested and collected in a serum-free medium. The suspension was subcutaneously injected into the left axilla of each nude mouse (1×10⁶ cells suspended in 0.2 mL medium per mouse). Tumor size was measured every three days using a Vernier Caliper once the tumors were palpable, and the weight of each mouse was recorded at this time. The tumor volume (mm³) was equal to length × width × width × 0.5 [45].

After xenograft tumors reached a mean size of 20–50 mm³, the mice were randomly divided into 4 groups (n=7 per group): CON, DZR, RT, and RT+DZR. In the experimental groups, tumors were irradiated with a single 10 Gy dose using a linear accelerator, and DZR was delivered as a single dose of 15.6 mg/100 g immediately after irradiation followed by 3.12 mg/100 g per week until the mice were euthanized. All mice in a group were euthanized when tumor length of most mice in the group exceeded 15 mm. The tumors were collected for immunohistochemical analysis.

Western blot analysis

Total cellular or tissue protein was extracted using RIPA lysis buffer. Proteins were separated using electrophoresis, transferred onto a polyvinylidene fluoride membrane, and separately incubated with the
following primary antibodies: GAPDH (AC002, 1:5000, Abclonal, Wuhan, China), Caspase-3 (9662s, 1:1000, Cell Signaling Technology), Cleaved Caspase-3 (9664T, 1:1000, Cell Signaling Technology). Bcl-2 (BA0412, 1:200, Boster, Wuhan, China), Bax (5023T, 1:1000, Cell Signaling Technology). The membranes were washed and incubated with the corresponding secondary antibody (HRP-goat anti-rabbit IgG or goat anti-mouse antibody, 1:10000) for 1 h at room temperature. Proteins were visualized using enhanced chemiluminescence and the G: BOX Chemi X system (Syngene) per the manufacturer’s guidelines.

**Immunohistochemical analysis**

For immunohistochemistry, paraffin-embedded heart sections were deparaffinized, rehydrated, and subjected to antigen retrieval. Next, samples were incubated with 5% bovine serum albumin at 4° C overnight with the primary antibody (NF-κB p65, 1:200, BIOSS, bs-0465R). The sections were then washed with TBST, incubated with peroxidase polymer-conjugated secondary antibody (1:5000) and DAB (both from Aspen Biological), and counterstained with hematoxylin. Three fields in each slice were selected and observed under 400× magnification. Brownish yellow nuclear staining was indicative of p65-positive cells. Total cell numbers and p65-positive cell numbers were counted to calculate the p65-positive cell ratio.

**Cardiac troponin I assay**

Blood samples were collected from rats at week 24 after RT from the heart apex at the moment of sacrifice, stored on ice, and subsequently centrifuged at 3000 ×g at 4° C for 15 min to obtain serum samples. Serum cTnI levels were assessed using a cTnI Assay Kit (ELK1552, ELK Biotechnology, Wuhan, China).

**Statistical analysis**

Results are expressed as the mean ± standard error of the mean (SEM). All data were statistically analyzed using a one-way analysis of variance with Bonferroni’s correction for multiple groups or Student’s t-test for two groups using GraphPad Prism 8.0 (GraphPad Software, CA, USA). The overall survival analysis was performed using the Kaplan-Meier method and evaluated using the log-rank test. *p* < 0.05 was considered statistically significant.

**Abbreviations**

DZR: dexrazoxane; RIHD: radiation induced heart disease; cTnI: cardiac troponin I; MACE: major adverse cardiac events; MHD: mean heart dose; OS: oxidative stress; ROS: reactive oxygen species; CON: control group; TEM: transmission electron microscopy; EF: left ventricular ejection fraction; DHE: dihydroethidium; i:p: intraperitoneal; C-caspase-3: cleaved caspase-3.

**AUTHOR CONTRIBUTIONS**

L.L., X.N., Y.H., and L.M. carried out experiments. L.L., X.N., and M. Y. analyzed data. P.Z. and X. Y. designed experiments. L.L., F.L., and X. N. wrote the paper. All authors approved of the final submitted and published versions.

**CONFLICTS OF INTEREST**

The authors declare that they have no conflicts of interest.

**FUNDING**

This work was supported by the National Natural Science Foundation of China (Grant no. 81472921, 81974483).

**REFERENCES**

1. Rajan Radha R, Chandrasekharan G. Pulmonary injury associated with radiation therapy - Assessment, complications and therapeutic targets. Biomed Pharmacother. 2017; 89:1092–104. [https://doi.org/10.1016/j.biopha.2017.02.106](https://doi.org/10.1016/j.biopha.2017.02.106) PMID:28298070

2. Rubin E, Camara J, Grayzel DM, Zak FG. Radiation-induced cardiac fibrosis. Am J Med. 1963; 34:71–75. [https://doi.org/10.1016/0002-9343(63)90039-1](https://doi.org/10.1016/0002-9343(63)90039-1) PMID:13982993

3. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Petö R, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013; 368:987–98. [https://doi.org/10.1056/NEJMoa1209825](https://doi.org/10.1056/NEJMoa1209825) PMID:23484825

4. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, van’t Veer MB, Baaijens MH, de Boer JP, Hart AA, Klokman WJ, Kuenen MA, Ouwens GM, Bartelink H, van Leeuwen FE. Late cardiotoxicity after treatment for hodgkin lymphoma. Blood. 2007; 109:1878–86. [https://doi.org/10.1182/blood-2006-07-034405](https://doi.org/10.1182/blood-2006-07-034405) PMID:17119114

5. Fillon M. Lung cancer radiation may increase the risk of major adverse cardiac events. CA Cancer J Clin. 2019; 69:435–37. [https://doi.org/10.3322/caac.21581](https://doi.org/10.3322/caac.21581) PMID:31545880
6. Hess SL, Jóhannsdóttir IM, Hamre H, Kiserud CE, Loge JH, Fosså SD. Adult survivors of childhood Malignant lymphoma are not aware of their risk of late effects. Acta Oncol. 2011; 50:653–59. https://doi.org/10.3109/0284186X.2010.550934 PMID: 21261507

7. Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 2011; 13:R64. https://doi.org/10.1186/bcr2901 PMID: 21689398

8. Lenneman CG, Sawyer DB. Cardio-oncology: an update on cardiotoxicity of cancer-related treatment. Circ Res. 2016; 118:1008–20. https://doi.org/10.1161/CIRCRESAHA.115.303633 PMID: 26987914

9. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL, Siegel RL. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019; 69:363–85. https://doi.org/10.3322/caac.21565 PMID: 31184787

10. Taunk NK, Haffty BG, Kostis JB, Goyal S. Radiation-induced heart disease: pathologic abnormalities and putative mechanisms. Front Oncol. 2015; 5:39. https://doi.org/10.3389/fonc.2015.00039 PMID: 25741474

11. Mosleh J. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016; 375:1457–67. https://doi.org/10.1056/NEJMra1100265 PMID: 27732808

12. Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014; 63:2751–68. https://doi.org/10.1016/j.jacc.2014.01.073 PMID: 24703918

13. Curigliano G, Cardinali D, Dent S, Criscitiello C, Aseyev O, Lenihan D, Cipolla CM. Cardiotoxicity of antinecancer treatments: epidemiology, detection, and management. CA Cancer J Clin. 2016; 66:309–25. https://doi.org/10.3322/caac.21341 PMID: 26919165

14. Zhang X, Zhu Y, Dong S, Zhang A, Lu Y, Li Y, Lv S, Zhang J. Role of oxidative stress in cardiotoxicity of antineoplastic drugs. Life Sci. 2019; 232:116526. https://doi.org/10.1016/j.lfs.2019.06.001 PMID: 31170418

15. Yu Z, Wang S, Zhang X, Li Y, Zhao Q, Liu T. Pterostilbene protects against myocardial ischemia/reperfusion injury via suppressing oxidative/nitrative stress and inflammatory response. Int Immunopharmacol. 2017; 43:7–15. https://doi.org/10.1016/j.intimp.2016.11.018 PMID: 27936461

16. Wang H, Wei J, Zheng Q, Meng L, Xin Y, Yin X, Jiang X. Radiation-induced heart disease: a review of classification, mechanism and prevention. Int J Biol Sci. 2019; 15:2128–38. https://doi.org/10.7150/ijbs.35460 PMID: 31592122

17. Asselin BL, Devidas M, Chen L, Franco VI, Pullen J, Borowitz MJ, Hutchinson RE, Ravindranath Y, Armenian SH, Camitta BM, Lipshultz SE. Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed t-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-hodgkin lymphoma: a report of the children’s oncology group randomized trial pediatric oncology group 9404. J Clin Oncol. 2016; 34:854–62. https://doi.org/10.1200/JCO.2015.60.8851 PMID: 26700126

18. Steiner R, Hellmann K. Dexrazoxane prevention of anthracycline cardiomyopathy. J Clin Oncol. 2013; 31:1379. https://doi.org/10.1200/JCO.2012.46.9908 PMID: 23439750

19. Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Barry EV, Asselin BL, Athale U, Clavell LA, Larsen E, Moghrabi A, Samson Y, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010; 11:950–61. https://doi.org/10.1016/S1470-2045(10)70204-7 PMID: 20850381

20. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, Colan SD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004; 351:145–53. https://doi.org/10.1056/NEJMoa035153 PMID: 15247354

21. Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2. J Am Coll Cardiol. 2017; 70:2552–565. https://doi.org/10.1016/j.jacc.2017.09.1095 PMID: 29145955

22. Marty M, Espié M, Llombart A, Monnier A, Rapoport BL, Stahalova V, and Dexrazoxane Study Group. Multicenter randomized phase III study of the
23. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiaro R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, et al, and ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37:2768–801. https://doi.org/10.1093/eurheartj/ehw211 PMID:27567406

24. Chun SG, Hu C, Choy H, Komaki RU, Timmerman RD, Schild SE, Bogart JA, Dobelbower MC, Bosch W, Galvin JM, Kavadi VS, Narayan S, Iyengar P, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial. J Clin Oncol. 2017; 35:56–62. https://doi.org/10.1200/JCO.2016.69.1378 PMID:28034064

25. Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015; 16:187–99. https://doi.org/10.1016/S1470-2045(14)71207-0 PMID:25601342

26. Wang K, Ebian MJ, Deal AM, Lipner M, Zagar TM, Wang Y, Mavroidis P, Lee CB, Jensen BC, Rosenman JG, Socinski MA, Stinchcombe TE, Marks LB. Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy. J Clin Oncol. 2017; 35:1387–94. https://doi.org/10.1200/JCO.2016.70.0229 PMID:28113017

27. Sridharan V, Tripathi P, Sharma SK, Moros EG, Corry PM, Lieblong BJ, Kaschina E, Unger T, Thöne-Reineke C, Hauer-Jensen M, Boerma M. Cardiac inflammation after local irradiation is influenced by the kallikrein-kinin system. Cancer Res. 2012; 72:4984–92. https://doi.org/10.1158/0008-5472.CAN-12-1831 PMID:22865451

28. Gürses I, Özeren M, Serin M, Yücel N, Erkal HŞ. Histopathological evaluation of melatonin as a protective agent in heart injury induced by radiation in a rat model. Pathol Res Pract. 2014; 210:863–71. https://doi.org/10.1016/j.prp.2014.08.006 PMID:25249491

29. Johnson S, Shaikh SB, Muneeea F, Rashmi B, Bhandary YP. Radiation induced apoptosis and pulmonary fibrosis: curcumin an effective intervention? Int J Radiat Biol. 2020; 96:709–17. https://doi.org/10.1080/09553002.2020.1739773 PMID:32149561

30. Ma CX, Zhao XK, Li YD. New therapeutic insights into radiation-induced myocardial fibrosis. Ther Adv Chronic Dis. 2019; 10:2040622319868383. https://doi.org/10.1177/2040622319868383 PMID:31448076

31. Slezak J, Kura B, Babal P, Barancik M, Ferko M, Frimmel K, Kalocayova B, Kukreja RC, Lazou A, Mezesova L, Okruhlcová L, Ravingerova T, Singal PK, et al. Potential markers and metabolic processes involved in the mechanism of radiation-induced heart injury. Can J Physiol Pharmacol. 2017; 95:1190–203. https://doi.org/10.1139/cjpp-2017-0121 PMID:28750189

32. Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, Cucchi G, Menatti E, Mangiavacchi M, Cavina R, Barbieri E, Gori S, Colombo A, et al, and ICOS-ONE Study Investigators. Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: the international CardioOncology society-one trial. Eur J Cancer. 2018; 94:126–37. https://doi.org/10.1016/j.ejca.2018.02.005 PMID:29567630

33. Boerma M, Roberto KA, Hauer-Jensen M. Prevention and treatment of functional and structural radiation injury in the rat heart by pentoxifylline and alph tocopherol. Int J Radiat Oncol Biol Phys. 2008; 72:170–77. https://doi.org/10.1016/j.ijrobp.2008.04.042 PMID:18632215

34. Salata C, Ferreira-Machado SC, De Andrade CB, Mencalha AL, Mandarim-De-Lacerda CA, de Almeida CE. Apoptosis induction of cardiomyocytes and subsequent fibrosis after irradiation and neoadjuvant chemotherapy. Int J Radiat Biol. 2014; 90:284–90. https://doi.org/10.3109/09553002.2014.887869 PMID:24467328

35. Ping Z, Peng Y, Lang H, Xinyong C, Zhiyi Z, Xiaocheng W, Hong Z, Liang S. Oxidative stress in radiation-induced cardiotoxicity. Oxid Med Cell Longev. 2020; 2020:3579143.
https://doi.org/10.1155/2020/3579143
PMID:32190171

36. Tapio S. Pathology and biology of radiation-induced cardiac disease. J Radiat Res. 2016; 57:439–48. https://doi.org/10.1093/jrr/rrw064 PMID:27422929

37. Varrielli G, Ameri P, Cadet D, Ghigo A, Madonna R, Marone G, Mercuro V, Monte I, Novo G, Parrella P, Pirozzi F, Pecoraro A, Spallarossa P, et al. Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective. Front Physiol. 2018; 9:167. https://doi.org/10.3389/fphys.2018.00167 PMID:29563880

38. Liberti MV, Locasale JW. The warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016; 41:211–18. https://doi.org/10.1016/j.tibs.2015.12.001 PMID:26778478

39. Idelchik MD, Begley U, Begley TJ, Melendez JA. Mitochondrial ROS control of cancer. Semin Cancer Biol. 2017; 47:57–66. https://doi.org/10.1016/j.semcancer.2017.04.005 PMID:28445781

40. Wei X, Xu Y, Xu FF, Chaiswing L, Schnell D, Noel T, Wang C, Chen J, St Clair DK, St Clair WH. RelB expression determines the differential effects of ascorbic acid in normal and cancer cells. Cancer Res. 2017; 77:1345–56. https://doi.org/10.1158/0008-5472.CAN-16-0785 PMID:28108513

41. Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, Liu LF. Topoisomerase Ibeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dextrazoxane. Cancer Res. 2007; 67:8839–46. https://doi.org/10.1158/0008-5472.CAN-07-1649 PMID:1785725

42. Sárközy M, Gászár R, Zvara Á, Kiscsatári L, Varga Z, Kővári B, Kovács MG, Szűcs G, Fábián G, Diószegi P, Cserni G, Puskás LG, Thum T, et al. Selective heart irradiation induces cardiac overexpression of the pro-hypertrophic miR-212. Front Oncol. 2019; 9:598. https://doi.org/10.3389/fonc.2019.00598 PMID:31380269

43. Sharma UC, Sonkawade SD, Sperryak JA, Sexton S, Nguyen J, Dahal S, Attwood KM, Singh AK, van Berlo JH, Pohkarel S. A small peptide Ac-SDKP inhibits radiation-induced cardiomyopathy. Circ Heart Fail. 2018; 11:e004867. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004867 PMID:30354563

44. Qin W, Liu B, Yi M, Li L, Tang Y, Wu B, Yuan X. Antifibrotic agent pirfenidone protects against development of radiation-induced pulmonary fibrosis in a murine model. Radiat Res. 2018; 190:396–403. https://doi.org/10.1667/RR15017.1 PMID:30016220

45. Zhu Y, Liu Y, Zhang C, Chu J, Wu Y, Li Y, Liu J, Li Q, Li S, Shi Q, Jin L, Zhao J, Yin D, et al. Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1. Nat Commun. 2018; 9:1595. https://doi.org/10.1038/s41467-018-03951-0 PMID:29686231